<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347295</url>
  </required_header>
  <id_info>
    <org_study_id>263.510</org_study_id>
    <nct_id>NCT00347295</nct_id>
  </id_info>
  <brief_title>Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.</brief_title>
  <official_title>A Randomised, Double-blinded, Double-dummy, Multi-center, Paralleled Study to Investigate the Safety and Efficacy of Brotizolam (Lendormin) Compared With Estazolam in Insomnia Outpatients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of Brotizolam in the treatment of patients with
      insomnia in comparison with that of Estazolam
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is intended to recruit 240 insomnia outpatients in this study, 120 patients receiving
      Brotizolam + Estazolam placebo (Test Group) and 120 patients given Estazolam + Brotizolam
      placebo (Control Group).

      Study Hypothesis:

      Brotizolam can be safely used in insomnia patients in China. And Brotizolam 0.25mg is
      non-inferior with Estazolam 1-2mg in treatment of insomnia patients in China

      Comparison(s):

      Estazolam 1-2mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date>January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of Sleeping Dysfunction Rating Scale (SDRS) total score of Brotizolam in comparison with Estazolam after a 14-day oral administration in patients with insomnia.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Clinical Global Impression- Improvement score(CGI-I) The Clinical Global Impression- Severity score (CGI-S) Effective rate Rebound phenomena</measure>
  </secondary_outcome>
  <enrollment>253</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brotizolam</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estazolam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion_Criteria:

        Patients will be eligible for enrollment of this study if they meet all of the following
        criteria:

          -  Willing and able to provide written informed consent

          -  Male or female, aged 18 - 65 (including 18 and 65)

          -  Diagnosed as insomnia by the criteria of CCMD-3:

        Exclusion_Criteria:

          -  Who received any central nervous system drugs within one week before visit 2(baseline)

          -  Continuous use of hypnotic agents for more than 3 months recently

          -  History of inefficiency with benzodiazepine-type hypnotics

          -  Who have a history of obvious hypersensitivity

          -  Hamilton Depression Rating Scale (HAMD)18

          -  Who was diagnosed with other mental illness

          -  With serious diseases of heart, liver and kidney, etc

          -  Who had sleep apnoea syndrome

          -  Who had epileptic seizures within one year

          -  With angle closure glaucoma that is acute or easy to occurred

          -  Whose AST or ALT values are 2 times of normal upper limit

          -  Whose Cr or BUN values are 2 times of normal upper limit

          -  Who are known to be prone to the abuse of alcohol (i.e. history of evidence of acute
             or chronic abuse), or any other addictive agents

          -  Who is participating in other clinical trial, or have participated in a clinical study
             of any other drug in one month prior to visit 2 (baseline). In addition, patients who
             has been randomized in this trial and then withdrew can not be enrolled again.

          -  All pregnant, lactational women and women who have the plan of pregnancy.

          -  Who are unwilling to or not able to complete the whole clinical trial

          -  Other patients who are unsuitable to be included in the trial judged by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Third Hospital of Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anding Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guanzhou Psychiatric Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hu Shan Hospital, Fu Dan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/23025837</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brotizolam</mesh_term>
    <mesh_term>Estazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

